BB Neurotrauma Assay
Advancing Brain Injury Diagnosis with Precision Biomarkers
The Neurotrauma Assay evaluates a targeted set of clinically relevant biomarkers to detect brain injury, neurological stress, and blood-brain barrier disruption. These markers provide measurable insight into how the brain responds to trauma—supporting clearer understanding and more informed next steps.
Key Biomarkers Assessed
- GFAP (Glial Fibrillary Acidic Protein)
- Indicates astroglial injury and disruption of the blood-brain barrier.
- NF-H (Neurofilament Heavy Chain)
- Detects axonal damage — critical for assessing diffuse axonal injuries.
- S100B (Calcium-Binding Protein B)
- Marker for blood-brain barrier permeability and brain cell damage.
- UCH-L1 (Ubiquitin C-Terminal Hydrolase-L1)
- Reflects neuronal cell body injury and neurodegeneration.
Why These Biomarkers Matter
Together, these biomarkers provide a more complete picture of brain health by identifying:
- Structural damage to brain cells
- Axonal injury and neurological disruption
- Blood-brain barrier integrity
- Early signals of neurodegenerative processes
This data helps move beyond symptoms alone—giving you objective insight into what’s happening at the biological level.
| Quick Facts | |
|---|---|
| Time to complete: 5–10 minutes | Sample type: At-home collection |
| Results: ~2–3 weeks | Privacy: Secure & confidential |
Frequently Asked Questions
Clarity you can act on. This testing is designed to give you clear, actionable insights—so you can make informed decisions with confidence. Below are answers to common questions to help guide you.
Want help interpreting your results? ExtendingMe Educators are available. Book a 30-minute one-on-one coaching session and receive personalized guidance tailored to your panel. (Applies to one panel per session.)